Seribantumab

All
Insights
Investors
Board of Directors
Leadership
Uncategorized
Our Partners
Scientific Advisory Committee
Publications
Newsroom

July 11, 2021

Manuscripts

Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors

Denlinger et al., Investigational New Drugs 2021

Read More